Exelixis Inc (EXEL)
Exelixis, Inc. is a NASDAQ-listed biotechnology company focused on discovering, developing, and commercializing medicines for difficult-to-treat cancers. Its portfolio includes CABOMETYX tablets for advanced renal cell carcinoma after prior anti-angiogenic therapy and COMETRIQ capsules for progressive and metastatic medullary thyroid cancer. Both products are based on cabozantinib, a multi-kinase inhibitor. The company also markets COTELLIC, used in combination treatment for certain advanced melanoma cases, and MINNEBRO, an oral non-steroidal mineralocorticoid receptor blocker approved for hypertension in Japan. In development, Exelixis is advancing several oncology programs, including zanzalintinib, XL309, XB010, XB628, and XB371. The company works with a range of pharmaceutical and biotechnology partners through collaborations and license agreements. Founded in 1994 and headquartered in Alameda, California, it changed its name from Exelixis Pharmaceuticals, Inc. in 2000.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EXEL
|
$62.03
|
11.4% Upside
|
Fair
|
$50.93
|
-8.5% Downside
|
Fair
|
Excellent
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
16.8x
|
7.2x
|
5.9x
|
13.958 B
|
12.716 B
|
1.2%
|
81.3%
|
15.2
|
—
|
110.1%
|
